Northern Trust
EVMN

Northern Trust’s Evommune Inc EVMN Stock Holding History

Northern Trust’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.83M Buy
79,755
+57,119
+252% +$1.29M ﹤0.01% 3023
2025
Q4 		$388K Buy
+22,636
New +$425K ﹤0.01% 3751

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Northern Trust's EVMN Position: Q1 2026 in Review

Northern Trust increased its Evommune Inc (EVMN) stake by 252% in Q1 2026, buying an estimated $1.29M and bringing the position to 79,755 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3023.

Northern Trust first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • Northern Trust held 79,755 shares of Evommune Inc worth $1.83M as of Q1 2026.
  • Northern Trust bought 57,119 Evommune Inc shares in Q1 2026, an estimated $1.29M.
  • Evommune Inc made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3023 holding.
  • Northern Trust first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.